07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

NovaDigm, Harbor-UCLA Medical Center deal

NovaDigm acquired exclusive, worldwide rights to Candida albicans hyphally regulated cell wall protein 1 ( Hyr1 ), a Candida vaccine antigen, from Harbor-UCLA Medical Center’s Los Angeles BioMedical Research Institute. NovaDigm plans to develop a...